1. Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla E et al.. (2010) Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene, 29 (37): 5171-81. [PMID:20581866]
2. Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD, Chen HW. (2010) ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res, 70 (22): 9402-12. [PMID:20864510]
3. Krakstad C, Tangen IL, Hoivik EA, Halle MK, Berg A, Werner HM, Ræder MB, Kusonmano K, Zou JX, Øyan AM et al.. (2015) ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget, 6 (29): 28440-52. [PMID:26308378]
4. Luo Y, Ye GY, Qin SL, Yu MH, Mu YF, Zhong M. (2015) ATAD2 Overexpression Identifies Colorectal Cancer Patients with Poor Prognosis and Drives Proliferation of Cancer Cells. Gastroenterol Res Pract, 2015: 936564. [PMID:26697062]
5. Zhang M, Zhang C, Du W, Yang X, Chen Z. (2016) ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker. Clin Transl Oncol, 18 (8): 776-81. [PMID:26527032]
To cite this family introduction, please use the following:
3.6.1.3 ATPases, introduction. Last modified on 05/04/2017. Accessed on 19/03/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=873.